ACT Brief: Data Fragmentation Risks Rise, Outsourcing Models Evolve, and FDA Pathways Face Pressure

In today’s ACT Brief, we examine how fragmented data collection continues to challenge trial quality, how hybrid outsourcing and AI are reshaping execution strategies, and why calls are growing for a risk-based FDA pathway for early-stage studies.